CoChat

Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers

Open access

Published version of a preprint

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

Although several groups have demonstrated that concomitant use of MEK and phosphoinositide 3-kinase (PI3K) inhibitors (MEKi/PI3Ki) can induce dramatic tumor regressions in mouse models of KRAS-mutant non–small cell lung cancer (NSCLC), ongoing clinical trials investigating this strategy have been underwhelming to date. While efficacy may be hampered by a narrow therapeutic index, the contribution of biologic heterogeneity in the response of KRAS-mutant NSCLCs to MEKi/PI3Ki has been largely unexplored. In this study, we find that most human KRAS-mutant NSCLC cell lines fail to undergo marked apoptosis in response to MEKi/PI3Ki, which is key for tumor responsiveness in vivo. This heterogeneity of apoptotic response occurs despite relatively uniform induction of growth arrest. Using a targeted short hairpin RNA screen of BCL-2 family members, we identify BIM, PUMA, and BCL-XL as key regulators of the apoptotic response induced by MEKi/PI3Ki, with decreased expression of BIM and PUMA relative to BCL-XL in cell lines with intrinsic resistance. In addition, by modeling adaptive resistance to MEKi/PI3Ki both in vitro and in vivo, we find that, upon the development of resistance, tumors have a diminished apoptotic response due to downregulation of BIM and PUMA. These results suggest that the inability to induce apoptosis may limit the effectiveness of MEKi/PI3Ki for KRAS-mutant NSCLCs by contributing to intrinsic and adaptive resistance to this therapy. Cancer Res; 74(11); 3146–56. ©2014 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-13-3728

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 41 references

Cited by

See all 74

Metadata

Authors
Hata, A. N., Yeo, A., Faber, A. C., Lifshits, E., Chen, Z., Cheng, K. A., Walton, Z., Sarosiek, K. A., Letai, A., Heist, R. S., Mino-Kenudson, M., Wong, K.-K., & Engelman, J. A.
Affiliations
Harvard University (US)
Corresponding author
Engelman, Jeffrey A.
Venue
Cancer Research
Published
2014-05-29
Volume
74
Issue
11
Pages
3146-3156
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2116796524
Cited by
74
References
41
Citations by year
2026: 2 · 2025: 1 · 2024: 3 · 2023: 2 · 2022: 6 · 2021: 3 · 2020: 5 · 2019: 8 · 2018: 10 · 2017: 6 · 2016: 13 · 2015: 9 · 2014: 6
FWCI
4.64
Type
journal article
Language
en
Open access
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Stand Up To Cancer
  • National Cancer Institute (R01CA166480, U01CA141457, RC2CA147940, R01CA122794, R01CA140594, P50CA090578, R01CA137181, R01CA137008)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords
KRAS-mutant non-small cell lung cancer, MEK inhibitors, PI3K inhibitors, combination therapy, apoptosis, Bcl-2 family proteins, building information modeling, PUMA, Bcl-xL, adaptive drug resistance, intrinsic drug resistance, growth arrest
MeSH terms
Phosphoinositide-3 Kinase Inhibitors, Animals, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mice, Nude, Mitochondria, Mutation, Signal Transduction, Apoptosis, ras Proteins, Proto-Oncogene Proteins c-bcl-2, Phosphatidylinositol 3-Kinases, MAP Kinase Signaling System, Cell Line, Tumor, Protein Kinase Inhibitors, Apoptosis Regulatory Proteins, bcl-X Protein, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers. https://app.cochat.ai/papers/10.1158/0008-5472.can-13-3728
The paper
Hata, A. N., Yeo, A., Faber, A. C., Lifshits, E., Chen, Z., Cheng, K. A., Walton, Z., Sarosiek, K. A., Letai, A., Heist, R. S., Mino-Kenudson, M., Wong, K.-K., & Engelman, J. A. (2014). Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers. Cancer Research. https://doi.org/10.1158/0008-5472.can-13-3728

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.